# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&...
- Reuters
TD Cowen analyst Ken Cacciatore downgrades IVERIC bio (NASDAQ:ISEE) from Outperform to Market Perform.
Baird analyst Colleen Kusy downgrades IVERIC bio (NASDAQ:ISEE) from Outperform to Neutral and announces $40 price target.
UBS analyst Eliana Merle downgrades IVERIC bio (NASDAQ:ISEE) from Buy to Neutral and raises the price target from $34 to $40.